• Publications
  • Influence
Testing the Right Target and Right Drug at the Right Stage
Drugs aimed at the initial stages of the Alzheimer’s disease pathology should be tested a decade before the onset of dementia. Alzheimer’s disease (AD) is the only leading cause of death for which noExpand
  • 365
  • 14
CD33 modulates TREM2: convergence of Alzheimer loci
We used a protein quantitative trait analysis in monocytes from 226 individuals to evaluate cross-talk between Alzheimer loci. The NME8 locus influenced PTK2B and the CD33 risk allele led to greaterExpand
  • 89
  • 10
In Vivo Tau, Amyloid, and Gray Matter Profiles in the Aging Brain
We provide a comparative in vivo examination of the brain network-based distribution of two hallmarks of Alzheimer's disease (AD) pathology in cognitively normal individuals: (1) Tau, detected with aExpand
  • 98
  • 9
Early role of vascular dysregulation on late-onset Alzheimer's disease based on multifactorial data-driven analysis
Multifactorial mechanisms underlying late-onset Alzheimer's disease (LOAD) are poorly characterized from an integrative perspective. Here spatiotemporal alterations in brain amyloid-β deposition,Expand
  • 361
  • 6
Functional connectivity in autosomal dominant and late-onset Alzheimer disease.
IMPORTANCE Autosomal dominant Alzheimer disease (ADAD) is caused by rare genetic mutations in 3 specific genes in contrast to late-onset Alzheimer disease (LOAD), which has a more polygenetic riskExpand
  • 57
  • 6
Florbetapir F 18 amyloid PET and 36-month cognitive decline:a prospective multicenter study
This study was designed to evaluate whether subjects with amyloid beta (Aβ) pathology, detected using florbetapir positron emission tomorgraphy (PET), demonstrated greater cognitive decline thanExpand
  • 139
  • 4
Amyloid-β 11C-PiB-PET imaging results from 2 randomized bapineuzumab phase 3 AD trials
Objective: To evaluate the effects of bapineuzumab on brain β-amyloid (Aβ) burden using 11C-Pittsburgh compound B (11C-PiB)-PET. Methods: Two phase 3 clinical trials, 1 each in apolipoprotein APOE ε4Expand
  • 87
  • 4
Depressive Symptoms and Biomarkers of Alzheimer's Disease in Cognitively Normal Older Adults.
Even low levels of depressive symptoms are associated with an increased risk of cognitive decline in older adults without overt cognitive impairment (CN). Our objective was to examine whether veryExpand
  • 46
  • 4
Longitudinal measurement and hierarchical classification framework for the prediction of Alzheimer’s disease
Accurate prediction of Alzheimer’s disease (AD) is important for the early diagnosis and treatment of this condition. Mild cognitive impairment (MCI) is an early stage of AD. Therefore, patients withExpand
  • 37
  • 2
Decreased body mass index in the preclinical stage of autosomal dominant Alzheimer’s disease
The relationship between body-mass index (BMI) and Alzheimer´s disease (AD) has been extensively investigated. However, BMI alterations in preclinical individuals with autosomal dominant AD (ADAD)Expand
  • 17
  • 2